Bavarian Nordic Starts Trial with Breast Cancer Vaccine

Bavarian Nordic A/S has announced that its US-based subsidiary BN ImmunoTherapeutics Inc. has received approval from the US Food and Drug Association, FDA, to start clinical trials with their breast cancer vaccine, MVA-BN-HER-2. Patient enrolment in a Phase I/II study in the US is expected to start as soon as possible.

In addition to the US study, BN ImmunoTherapeutics is also planning to start a Phase I/II study with MVA-BN-HER2 in Europe. The two studies are expected to enrol up to 60 patients.

The studies are designed to evaluate the safety and tolerability of MVA-BN-HER2. The studies will also evaluate the biological activity of the vaccine by measuring HER-2 specific immune responses in treated patients. In addition, the effect of the vaccine on the clinical progress of the patients and on tumour growth will also be explored.

For further information please contact:

Rolf Sass Sørensen
Vice President, IR & Communications

Tel: +45 33 26 83 83

Email: bn@bavarian-nordic.com

Or visit: www.bavarian-nordic.com